Rytary/IPX066 (Parkinson’s Disease) – Market analysis to 2022 - PowerPoint PPT Presentation

About This Presentation
Title:

Rytary/IPX066 (Parkinson’s Disease) – Market analysis to 2022

Description:

Get a detailed report at . Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Rytary, also known as IPX066, is a levodopa-based product for the treatment of early and advanced Parkinson’s disease. It was developed by the generics manufacturer Impax Laboratories and contains a capsule with different-sized beads that dissolve at different rates, releasing a 1:4 ratio of carbidopa: levodopa – PowerPoint PPT presentation

Number of Views:262

less

Transcript and Presenter's Notes

Title: Rytary/IPX066 (Parkinson’s Disease) – Market analysis to 2022


1
Rytary/IPX066 (Parkinsons Disease) Forecast
and Market analysis to 2022
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_marketoptimizer.org with
your contact details and questions if any.
  • Published Mar 2014
  • Single User PDF US 3495
  • Corporate User PDF US 10485

2
Rytary/IPX066 (Parkinsons Disease) Forecast
and Market analysis to 2022
  • Parkinsons disease is a progressive condition
    that is characterized by bradykinesia, muscular
    rigidity, tremor, and postural instability. As
    the second most common neurodegenerative
    disorder, Parkinsons disease may affect
    individuals of any age but prevalence is
    increased with age and it is most common in the
    elderly. Dopaminergic therapies have been fairly
    effective in treating bradykinesia, but several
    unmet needs remain. Some needs will be met during
    the forecast period from 2012-2022, while others,
    such as the need for disease-modifying drugs,
    will remain.
  • Researcher expects that advancements will be
    made in levodopa administration and that four new
    molecular entities will be introduced to the
    market by 2022, these factors along with
    increased patient numbers from an aging
    population will drive the market during the
    forecast period.

Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
3
Rytary/IPX066 (Parkinsons Disease) Forecast
and Market analysis to 2022
  • Rytary, also known as IPX066, is a levodopa-based
    product for the treatment of early and advanced
    Parkinsons disease. It was developed by the
    generics manufacturer Impax Laboratories and
    contains a capsule with different-sized beads
    that dissolve at different rates, releasing a 14
    ratio of carbidopa levodopa
  • Scope
  • Overview of Parkinsons disease, including
    epidemiology, etiology, symptoms, diagnosis,
    pathology and treatment guidelines as well as an
    overview on the competitive landscape.
  • Detailed information on Rytary including product
    description, safety and efficacy profiles as well
    as a SWOT analysis.
  • Sales forecast for Rytary for the top six
    countries from 2012 to 2022.
  • Sales information covered for the US, France,
    Germany, Italy, Spain and the UK.

Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
4
Rytary/IPX066 (Parkinsons Disease) Forecast
and Market analysis to 2022
  • Reasons to buy
  • Understand and capitalize by identifying products
    that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding
    the changing competitive landscape for
    Parkinsons disease
  • Effectively plan your MA and partnership
    strategies by identifying drugs with the most
    promising sales potential
  • Make more informed business decisions from
    insightful and in-depth analysis of Rytary
    performance
  • Obtain sales forecast for Rytary from 2012-2022
    in the top six countries (the US, France,
    Germany, Italy, Spain and the UK).
  • Get a detailed report at http//www.marketoptimize
    r.org/rytaryipx066-parkinsons-disease-forecast-and
    -market-analysis-to-2022.html .

Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
5
Rytary/IPX066 (Parkinsons Disease) Forecast
and Market analysis to 2022
  • About Us
  • marketoptimizer.org is an online market research
    reports library of 250,000 in-depth studies of
    over 5000 micro markets. Our database includes
    reports by leading publishers from across the
    globe. We provide 24/7 online and offline support
    service to our customers. marketoptimizer.org
    also offers company data, country profiles,
    trends, information and analysis on the sector of
    your interest.
  • Visit Us _at_
  • http//www.marketoptimizer.org
  • Follow Us

Call Now 1 888 391 5441 Email sales _at_
sales_at_marketoptimizer.org
Write a Comment
User Comments (0)
About PowerShow.com